Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus

Journal of Virology

Volumn 88, Issue 3, 2014, Pages 1725-1739

  Prentoe, Jannick ^a   Serre, Stéphanie B N ^a   Ramirez, Santseharay ^a   Nicosia, Alfredo ^b,c   Gottwein, Judith M ^a   Bukh, Jens ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CD81 ANTIGEN; GLYCOPROTEIN E2; LOW DENSITY LIPOPROTEIN RECEPTOR; SCAVENGER RECEPTOR BI; VIRUS RNA;

ANTIGEN EXPRESSION; ARTICLE; CHROMOSOME DELETION; GENE SILENCING; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HYPERVARIABLE REGION 1; INOCULATION; LIFE CYCLE; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS LIFE CYCLE; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION;

CELL LINE, TUMOR; HEPACIVIRUS; HEPATITIS C; HUMANS; RECEPTORS, LDL; RECEPTORS, VIRUS; SCAVENGER RECEPTORS, CLASS B; SEQUENCE DELETION; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 84892452345     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02017-13     Document Type: Article

References (53)

1. Alter HJ, Seeff LB. 2000. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 20:17-35. http://dx.doi.org/10.1055/s-2000-9505.
2. Gottwein JM, Bukh J. 2008. Cutting the Gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Adv. Virus Res. 71:51-133. http://dx.doi.org/10.1016/S0065-3527(08)00002-X.
3. Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, Gottwein JM, Bukh J. 2011. Hypervariable region 1 differentially impacts viability of hepatitisCvirus strains of genotypes 1 to 6 and impairs virus neutralization. J. Virol. 85:2224-2234. http://dx.doi.org/10.1128/JVI.01594-10.
4. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, Patel AH, Dubuisson J, Ball JK, Cosset FL. 2005. Characterization of hostrange and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41:265-274. http://dx.doi.org/10.1002/hep .20542.
5. Scheel TK, Prentoe J, Carlsen TH, Mikkelsen LS, Gottwein JM, Bukh J. 2012. Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems. PLoS Pathog. 8:e1002696. http://dx.doi.org/10.1371/journal.ppat.1002696.
6. Meredith LW, Wilson GK, Fletcher NF, McKeating JA. 2012. Hepatitis C virus entry: beyond receptors. Rev. Med. Virol. 22:182-193. http://dx .doi.org/10.1002/rmv.723.
7. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805. http://dx.doi.org/10.1038/nature05654.
8. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886. http://dx.doi.org/10.1038/nature07684.
9. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:5017-5025. http://dx.doi.org/10.1093/emboj/cdf529.
10. Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T. 2004. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 101:7270-7274. http://dx.doi.org/10.1073/pnas.0402253101.
11. Farquhar MJ, Hu K, Harris HJ, Davis C, Brimacombe CL, Fletcher SJ, Baumert TF, Rappoport JZ, Balfe P, McKeating JA. 2012. Hepatitis C virus induces CD81 and claudin-1 endocytosis. J. Virol. 86:4305-4316. http://dx.doi.org/10.1128/JVI.06996-11.
12. Brazzoli M, Bianchi A, Filippini S, Weiner A, Zhu Q, Pizza M, Crotta S. 2008. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J. Virol. 82:8316-8329. http://dx .doi.org/10.1128/JVI.00665-08.
13. Chang KS, Jiang J, Cai Z, Luo G. 2007. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 81:13783-13793. http://dx.doi.org/10.1128/JVI.01091-07.
14. Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K. 2010. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J. Virol. 84:12048-12057. http://dx.doi.org/10.1128/JVI.01063-10.
15. Cun W, Jiang J, Luo G. 2010. The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus. J. Virol. 84:11532-11541. http://dx.doi .org/10.1128/JVI.01021-10.
16. Maillard P, Huby T, Andreo U, Moreau M, Chapman J, Budkowska A. 2006. The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/ClaI is mediated by ApoB-containing lipoproteins. FASEB J. 20:735-737. http://dx.doi.org/10.1096/fj.05-4728fje.
17. Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T. 2012. Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology 56:484-491. http://dx.doi.org/10.1002/hep.25665.
18. Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. 2012. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J. Virol. 86:7256-7267. http://dx.doi.org/10.1128/JVI.07222-11.
19. Kobayashi F, Yamada S, Taguwa S, Kataoka C, Naito S, Hama Y, Tani H, Matsuura Y, Sugahara K. 2012. Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus. Glycoconj. J. 29:211-220. http://dx.doi.org/10.1007/s10719-012-9388-z.
20. Shi Q, Jiang J, Luo G. 2013. Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J. Virol. 87:6866-6875. http://dx.doi.org/10.1128/JVI.03475-12.
21. Owen DM, Huang H, Ye J, Gale M, Jr. 2009. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with lowdensity lipoprotein receptor. Virology 394:99-108. http://dx.doi.org/10 .1016/j.virol.2009.08.037.
22. Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, Terce F, Duverlie G, Rouille Y, Dubuisson J. 2012. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 55:998-1007. http://dx.doi.org/10.1002/hep.25501.
23. Ploss A, Evans MJ. 2012. Hepatitis C virus host cell entry. Curr. Opin. Virol. 2:14-19. http://dx.doi.org/10.1016/j.coviro.2011.12.007.
24. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL. 2005. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 79:8217-8229. http://dx.doi.org/10.1128/JVI.79.13.8217-8229.2005.
25. Dao Thi VL, Granier C, Zeisel MB, Guerin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M. 2012. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J. Biol. Chem. 287:31242-31257. http://dx.doi.org/10.1074/jbc.M112.365924.
26. Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Foung SK, Pecheur EI, Pietschmann T. 2010. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J. Virol. 84:5751-5763. http://dx.doi.org/10 .1128/JVI.02200-09.
27. Forns X, Thimme R, Govindarajan S, Emerson SU, Purcell RH, Chisari FV, Bukh J. 2000. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc. Natl. Acad. Sci. U.S.A. 97: 13318-13323. http://dx.doi.org/10.1073/pnas.230453597.
28. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016.
29. Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J, Lisby G, Bukh J. 2007. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 133:1614-1626. http://dx.doi.org/10.1053/j.gastro.2007.08.005.
30. Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ, Eugen-Olsen J, Bukh J. 2008. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl. Acad. Sci. U.S.A. 105:997-1002. http://dx.doi .org/10.1073/pnas.0711044105.
31. Bartosch B, Dubuisson J, Cosset FL. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642. http://dx.doi.org/10.1084/jem .20021756.
32. Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, Cosset FL, Purcell RH, Bukh J. 2005. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc. Natl. Acad. Sci. U.S.A. 102:4560-4565. http://dx.doi.org/10.1073/pnas.0501275102.
33. Serre SB, Krarup HB, Bukh J, Gottwein JM. 2013. Identification of IFN-alpha induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance. J. Virol. 87: 12776-12793. http://dx.doi.org/10.1128/JVI.00901-13.
34. Meuleman P, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, Sheahan T, Grzyb K, Cortese R, Rice CM, Leroux-Roels G, Nicosia A. 2012. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 55:364-372. http://dx.doi.org/10.1002/hep.24692.
35. Nguyen AT, Hirama T, Chauhan V, Mackenzie R, Milne R. 2006. Binding characteristics of a panel of monoclonal antibodies against the ligand binding domain of the human LDLr. J. Lipid Res. 47:1399-1405. http://dx.doi.org/10.1194/jlr.M600130-JLR200.
36. Weisgraber KH, Innerarity TL, Harder KJ, Mahley RW, Milne RW, Marcel YL, Sparrow JT. 1983. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J. Biol. Chem. 258:12348-12354.
37. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:25-27. http://dx.doi.org/10.1038/nm1698.
38. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. 1994. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J. Virol. 68:6147-6160.
39. Albecka A, Montserret R, Krey T, Tarr AW, Diesis E, Ball JK, Descamps V, Duverlie G, Rey F, Penin F, Dubuisson J. 2011. Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. J. Virol. 85:1777-1792. http://dx.doi.org/10.1128/JVI.02170-10.
40. Carlsen TH, Scheel TK, Ramirez S, Foung SK, Bukh J. 2013. Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry. J. Virol. 87:1385-1399. http://dx.doi .org/10.1128/JVI.00684-12.
41. Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, Spengler U, Weis N, Bukh J. 2011. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. J. Virol. 85:2891-2906. http://dx.doi.org/10.1128/JVI.01605-10.
42. Russell RS, Meunier JC, Takikawa S, Faulk K, Engle RE, Bukh J, Purcell RH, Emerson SU. 2008. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 105:4370-4375. http://dx.doi.org/10.1073/pnas.0800422105.
43. Roccasecca R, Ansuini H, Vitelli A, Meola A, Scarselli E, Acali S, Pezzanera M, Ercole BB, McKeating J, Yagnik A, Lahm A, Tramontano A, Cortese R, Nicosia A. 2003. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J. Virol. 77:1856-1867. http://dx .doi.org/10.1128/JVI.77.3.1856-1867.2003.
44. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A. 2010. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J. Virol. 84:34-43. http://dx.doi.org/10.1128/JVI.02199-08.
45. Mazumdar B, Banerjee A, Meyer K, Ray R. 2011. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology 54:1149-1156. http://dx.doi.org/10.1002/hep.24523.
46. Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA. 2011. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J. Virol. 85:596-605. http://dx.doi.org/10 .1128/JVI.01592-10.
47. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, Schwarz A, Desombere I, Roels GL, Balfe P, McKeating JA. 2008. HepatitisCvirus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47:17-24. http://dx.doi.org/10.1002/hep.21959.
48. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. 2010. Characterization of the envelope glycoproteins associated with infectious hepatitisCvirus. J. Virol. 84:10159-10168. http://dx.doi.org/10 .1128/JVI.01180-10.
49. Koutsoudakis G, Dragun J, Perez-del-Pulgar S, Coto-Llerena M, Mensa L, Crespo G, Gonzalez P, Navasa M, Forns X. 2012. Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. PLoS One 7:e52651. http://dx .doi.org/10.1371/journal.pone.0052651.
50. Tao W, Xu C, Ding Q, Li R, Xiang Y, Chung J, Zhong J. 2009. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles. Virology 395:67-76. http://dx.doi .org/10.1016/j.virol.2009.09.006.
51. Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA. 2008. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J. Virol. 82:12020-12029. http://dx.doi.org/10.1128/JVI.01569-08.
52. Li X, Kan HY, Lavrentiadou S, Krieger M, Zannis V. 2002. Reconstituted discoidal ApoE-phospholipid particles are ligands for the scavenger receptor BI. The amino-terminal 1-165 domain of ApoE suffices for receptor binding. J. Biol. Chem. 277:21149-21157. http://dx.doi.org/10 .1074/jbc.M200658200.
53. Zahid MN, Turek M, Xiao F, Dao TV, Guerin M, Fofana I, Bachellier P, Thompson J, Delang L, Neyts J, Bankwitz D, Pietschmann T, Dreux M, Cosset FL, Grunert F, Baumert TF, Zeisel MB. 2013. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 57:492-504. http://dx.doi.org/10.1002/hep.26097.